A Scottish cancer drug discovery accelerator has appointed former non-executive director Nicola Broughton as its first chief business officer.
Cumulus Oncology also appointed Dr Diane Seimetz and Dr Sally Waterman as non-executive directors.
Broughton, a former investment director at Mercia Asset Management and co-founder of Oskare Capital, joined Cumulus’ advisory board in 2020. She also chairs genetic sequencing specialist Wobble Genomics, a spin-out from the University of Edinburgh’s Roslin Institute.
Seimetz was the former executive vice president and chief scientific officer at the Fresenius Group, leading a team that developed a number of biopharmaceutical products. She was also the co-founder and former chief executive at Biopharma Excellence.
Waterman was the former chief operating officer at Medherant - a clinical-stage pharmaceutical company with a novel drug delivery technology - and prior to this was senior vice president corporate development at Abzena - a company offering antibody drug conjugate and other services.
Edinburgh-headquartered Cumulus was founded in 2017 to create spin-out companies around novel anti-cancer therapies that are fast-tracked through development and target cancers that don’t respond well to existing treatments.
Cumulus secured a £1.7m investment round led by Eos Advisory last July and in September 2020 founded its first spin-out, Modulus Oncology, alongside the University of Sheffield.
Cumulus chief executive and co-founder Clare Wareing said: “We have stepped up our international activity and oncology asset discovery process markedly over the last twelve months, and Diane, Sally and Nicola’s appointments significantly strengthen both our advisory and executive teams.
"Nicola has been invaluable as an adviser, then non-executive director over the last year, and we are excited to have her as our first chief business officer.
Don't miss the latest headlines with our twice-daily newsletter - sign up here for free.
